Clinical Trials Browser

Phase 1/2 × Melanoma × Blood Component Removal × Clear all

NCT03325101 2025-06-12

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Phase 1/2 Terminated

7 enrolled 11 charts

Melanoma